The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Practical considerations for physicians managing patients with CLL in the frontline setting
In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, briefly mentions some practical considerations for physicians managing patients with chronic lymphocytic leukemia (CLL) in the frontline setting, highlighting the importance of a personalized and patient-centered treatment strategy. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The practical takeaway is not so easy because it’s not that you can say this type of patient has this type of treatment. I think the practical takeaway is that do the risk factor assessment like TP53 and IGHV status, assess the patient’s history, his expectations also for the treatment, if it’s more important for him to have a long time without treatment, a long treatment-free survival, deep remission, or if the patient is rather interested in having fewer visits at his physician’s desk, also depending on his environment, his family...
The practical takeaway is not so easy because it’s not that you can say this type of patient has this type of treatment. I think the practical takeaway is that do the risk factor assessment like TP53 and IGHV status, assess the patient’s history, his expectations also for the treatment, if it’s more important for him to have a long time without treatment, a long treatment-free survival, deep remission, or if the patient is rather interested in having fewer visits at his physician’s desk, also depending on his environment, his family. And depending on that, you can then choose the treatment with the patient. In summary, the good news, as long as you don’t give any chemotherapy, there is not so much you can do wrong with your patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
